Željko Vojnović

Data from Trilaciclib Prior to Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer: Final Efficacy and Subgroup Analysis from a Randomized Phase II Study

Antoinette R. Tan, Gail Shaw Wright, Anu R. Thummala, Michael A. Danso et autres

AbstractPurpose: We report final antitumor efficacy results from a phase II study of trilaciclib, an intravenous cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, administered prior to gemcitabine plus carboplatin (GCb) in patients with metastatic triple-negative breast cancer (NCT02978716). Patients and Methods: Patients were randomized …

Data from Trilaciclib Prior to Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer: Final Efficacy and Subgroup Analysis from a Randomized Phase II Study

Antoinette R. Tan, Gail Shaw Wright, Anu R. Thummala, Michael A. Danso et autres

AbstractPurpose: We report final antitumor efficacy results from a phase II study of trilaciclib, an intravenous cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, administered prior to gemcitabine plus carboplatin (GCb) in patients with metastatic triple-negative breast cancer (NCT02978716). Patients and Methods: Patients were randomized …

Supplementary Data from Trilaciclib Prior to Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer: Final Efficacy and Subgroup Analysis from a Randomized Phase II Study

Antoinette R. Tan, Gail Shaw Wright, Anu R. Thummala, Michael A. Danso et autres

Supplementary Data from Trilaciclib Prior to Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer: Final Efficacy and Subgroup Analysis from a Randomized Phase II Study

Supplementary Data from Trilaciclib Prior to Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer: Final Efficacy and Subgroup Analysis from a Randomized Phase II Study

Antoinette R. Tan, Gail Shaw Wright, Anu R. Thummala, Michael A. Danso et autres

Supplementary Data from Trilaciclib Prior to Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer: Final Efficacy and Subgroup Analysis from a Randomized Phase II Study

Clinical guidelines for diagnosis, treatment and monitoring of patients with invasive breast cancer – Croatian Oncology Society (BC-3 COS)

Ingrid Belac-Lovasić, Martina Bašić Koretić, Paula Podolski, Natalija Dedić Plavetić et autres

SAŽETAK.Rak dojke je najčešći zloćudni tumor u žena koji se može probirom, redovitim kontrolama i zdravstvenim odgojem otkriti u ranim stadijima bolesti i uspješno liječiti.Metode liječenja uključuju kirurgiju, kemoterapiju, radioterapiju, endokrinu terapiju, imunoterapiju, ciljanu terapiju te simptomatsko-suportivnu terapiju, koja se primjenjuje ovisno …

hr (code pays fourni par la source)

Efficacy and Safety of Autologous Dendritic Cell–Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer

Nicholas J. Vogelzang, Tomasz M. Beer, Winald R. Gerritsen, Stéphane Marie. Oudard et autres

IMPORTANCE: DCVAC/PCa is an active cellular immunotherapy designed to initiate an immune response against prostate cancer. OBJECTIVE: To evaluate the efficacy and safety of DCVAC/PCa plus chemotherapy followed by DCVAC/PCa maintenance treatment in patients with metastatic castration-resistant prostate cancer (mCRPC). DESIGN, SETTING, …

us, nl, fr, pl, cz, gb, de, rs, by, pt (code pays fourni par la source)

Trilaciclib Prior to Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer: Final Efficacy and Subgroup Analysis from a Randomized Phase II Study

Antoinette R. Tan, Gail Shaw Wright, Anu R. Thummala, Michael A. Danso et autres

PURPOSE: We report final antitumor efficacy results from a phase II study of trilaciclib, an intravenous cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, administered prior to gemcitabine plus carboplatin (GCb) in patients with metastatic triple-negative breast cancer (NCT02978716). PATIENTS AND METHODS: Patients were randomized …

us, rs, hr, at, mk (code pays fourni par la source)

1634P Communication specifics with cancer patients during the COVID-19 pandemic in Croatia: Can a virtual visit meet the needs of cancer patients?

Renata Kelemenić-Dražin, Nikša Sviličić, Anuška Budisavljević, Natalija Dedić Plavetić et autres

hr (code pays fourni par la source)

Impact of the coronavirus disease pandemic on cancer care in Croatia: a multicentre cross-sectional study

Renata Kelemenić-Dražin, Anuška Budisavljević, Natalija Dedić Plavetić, Iva Kardum Fucak et autres

PURPOSE: The coronavirus disease (COVID-19) pandemic has greatly affected the oncology community worldwide. Lockdowns, an epidemiological measure, have made it difficult for oncologists to provide care. In this study, we analysed the impact of the COVID-19 pandemic on Croatian cancer care. METHODS: …

hr (code pays fourni par la source)

Impact of the COVID-19 outbreak on the level of distress in patients with breast cancer

Anuška Budisavljević, Renata Kelemenić-Dražin, Natalija Dedić Plavetić, Iva Kardum Fucak et autres

Abstract PD1-06: Trilaciclib improves overall survival when given with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: Final analysis of a randomized phase 2 trial

Joyce A O'Shaughnessy, Gail Shaw Wright, Anu R. Thummala, Michael A. Danso et autres

Abstract Background Trilaciclib is an intravenous (IV) cyclin-dependent kinase 4/6 (CDK4/6) inhibitor. Preliminary data showed that adding trilaciclib prior to gemcitabine plus carboplatin (GCb) significantly increased overall survival (OS) compared with GCb alone among patients with metastatic triple-negative breast cancer (mTNBC) (Tan …

us, rs, hr, at (code pays fourni par la source)

Trilaciclib improves overall survival when given with gemcitabine/carboplatin (GC) in patients with metastatic triple negative breast cancer (mTNBC) in a randomized phase II trial

Joyce A O'Shaughnessy, Gail Shaw Wright, AR Thummala, Michael A. Danso et autres

us, rs, hr, mk (code pays fourni par la source)